|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/20 Teladoc Health, Inc. 10-Q 3/31/20 73:6.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 951K
2: EX-10.1 Material Contract HTML 58K
3: EX-10.2 Material Contract HTML 50K
4: EX-21.1 Subsidiaries List HTML 31K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
33: R1 Document and Entity Information HTML 76K
66: R2 Consolidated Balance Sheets HTML 101K
45: R3 Consolidated Balance Sheets (Parenthetical) HTML 34K
23: R4 Consolidated Statements of Operations HTML 70K
32: R5 Consolidated Statements of Comprehensive Loss HTML 42K
65: R6 Consolidated Statements of Stockholders' Equity HTML 66K
(Deficit)
44: R7 Consolidated Statements of Cash Flows HTML 102K
21: R8 Organization and Description of Business HTML 26K
34: R9 Basis of Presentation and Principles of HTML 36K
Consolidation
35: R10 Revenue HTML 55K
26: R11 Business Acquisitions HTML 24K
51: R12 Intangible Assets, Net HTML 89K
72: R13 Leases HTML 24K
36: R14 Accrued Expenses and Other Current Liabilities HTML 51K
27: R15 Goodwill HTML 31K
52: R16 Fair Value Measurements HTML 71K
73: R17 Revolving Credit Facility HTML 24K
37: R18 Convertible Senior Notes HTML 98K
25: R19 Legal Matters HTML 29K
54: R20 Common Stock and Stockholders' Equity HTML 138K
59: R21 Income Taxes HTML 26K
40: R22 Basis of Presentation and Principles of HTML 46K
Consolidations (Policies)
14: R23 Revenue (Tables) HTML 44K
55: R24 Fair Value Measurements (Tables) HTML 69K
60: R25 Intangible Assets, Net (Tables) HTML 89K
41: R26 Goodwill (Tables) HTML 31K
15: R27 Accrued Expenses and Other Current Liabilities HTML 51K
(Tables)
53: R28 Convertible Senior Notes (Tables) HTML 78K
61: R29 Common Stock and Stockholders' Equity (Tables) HTML 131K
71: R30 Organization and Description of Business (Details) HTML 34K
49: R31 Basis of Presentation and Principles of HTML 49K
Consolidation - VIE (Details)
30: R32 Basis of Presentation and Principles of HTML 31K
Consolidation - Segment and Foreign Operations
(Details)
39: R33 Revenue - Other Disclosures (Details) HTML 32K
70: R34 Revenue - Disaggregation and Other (Details) HTML 44K
48: R35 Business Acquisitions (Details) HTML 25K
29: R36 Intangible Assets, Net - Summary (Details) HTML 71K
38: R37 Goodwill (Details) HTML 26K
69: R38 Leases - Other (Details) HTML 30K
50: R39 Accrued Expenses and Other Current Liabilities HTML 54K
(Details)
64: R40 Fair Value Measurements - Recurring (Details) HTML 53K
57: R41 Fair Value Measurements - Level 3 (Details) HTML 32K
18: R42 Revolving Credit Facility (Details) HTML 31K
43: R43 Convertible Senior Notes - Due 2025 - Terms HTML 65K
(Details)
63: R44 Convertible Senior Notes - Due 2025 - Summary HTML 51K
(Details)
56: R45 Convertible Senior Notes - Due 2022 - Terms HTML 65K
(Details)
17: R46 Convertible Senior Notes - Due 2022 - Summary HTML 51K
(Details)
42: R47 Common Stock and Stockholders' Equity - HTML 24K
Capitalization (Details)
62: R48 Common Stock and Stockholders' Equity - Stock Plan HTML 95K
and Stock Options (Details)
58: R49 Common Stock and Stockholders' Equity - Vesting HTML 28K
(Details)
46: R50 Common Stock and Stockholders' Equity - Fair Value HTML 50K
Assumptions (Details)
67: R51 Common Stock and Stockholders' Equity - Restricted HTML 78K
Stock Units (Details)
31: R52 Common Stock and Stockholders' Equity - HTML 74K
Performance Stock Units (Details)
20: R53 Common Stock and Stockholders' Equity - Employee HTML 45K
Stock Purchase Plan (Details)
47: R54 Common Stock and Stockholders' Equity - HTML 33K
Compensation Costs (Details)
68: R55 Income Taxes (Details) HTML 27K
28: XML IDEA XML File -- Filing Summary XML 124K
22: XML XBRL Instance -- tdoc-20200429x10q_htm XML 1.51M
16: EXCEL IDEA Workbook of Financial Reports XLSX 67K
10: EX-101.CAL XBRL Calculations -- tdoc-20200429_cal XML 133K
11: EX-101.DEF XBRL Definitions -- tdoc-20200429_def XML 524K
12: EX-101.LAB XBRL Labels -- tdoc-20200429_lab XML 1.12M
13: EX-101.PRE XBRL Presentations -- tdoc-20200429_pre XML 856K
9: EX-101.SCH XBRL Schema -- tdoc-20200429 XSD 144K
19: JSON XBRL Instance as JSON Data -- MetaLinks 276± 440K
24: ZIP XBRL Zipped Folder -- 0001558370-20-004629-xbrl Zip 212K
| tdoc_Ex_10_2 |
Exhibit 10.2
|
|
|
TELADOC HEALTH, INC. |
PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE
Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (f/k/a Teladoc, Inc.) (the “Company”).
The Company hereby grants to the participant listed below (“Participant”) the Restricted Stock Units described in this Grant Notice (the “PSUs”), subject to the terms and conditions of the Plan and the Performance Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”), both of which are incorporated into this Grant Notice by reference.
|
Participant: |
[_________] |
|
Grant Date: |
|
|
Number of PSUs: |
[_________] |
|
Performance Period: |
January 1, 2020 through December 31, 2020 |
|
Vesting Schedule: |
The PSUs will vest in accordance with the vesting schedule set forth in Exhibit A. |
By Participant’s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.
|
|
|
|
|
|
|
TELADOC HEALTH, INC. |
|
PARTICIPANT |
||
|
By: |
|
|
||
|
Print Name: |
|
Print Name: |
||
|
Title: |
|
|
||
Exhibit A
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.
ARTICLE I.
GENERAL
1.1 Award of PSUs and Dividend Equivalents.
(a) The Company has granted the PSUs to Participant effective as of the grant date set forth in the Grant Notice (the “Grant Date”). The number of PSUs stated in the Grant Notice is the target number of PSUs that may be earned under this Award (the “Target Number of PSUs”). The number of PSUs that may actually be earned under this Award ranges from between 50% and 200% of the Target Number of PSUs. Each earned PSU represents the right to receive one Share or, at the option of the Administrator, an amount of cash, in either case, as set forth in this Agreement. Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the PSUs have vested.
(b) The Company hereby grants to Participant, with respect to each earned PSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable PSU is settled, forfeited or otherwise expires. Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share. The Company will establish a separate Dividend Equivalent bookkeeping account (a “Dividend Equivalent Account”) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid.
1.2 Incorporation of Terms of Plan. The PSUs and Dividend Equivalents are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.
1.3 Unsecured Promise. The PSUs and Dividend Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company’s general assets.
ARTICLE II.
VESTING; FORFEITURE AND SETTLEMENT
2.1 Vesting; Forfeiture.
(a) The PSUs will be earned, if at all, based on the Company’s achievement of the performance conditions fixed by the Compensation Committee of the Board of Directors of the Company over the Performance Period set forth in the Grant Notice (the “Performance Period”). Within ninety (90) days following completion of the Performance Period, the Administrator will determine, in its sole and absolute discretion, the extent to which the performance conditions have been satisfied (the date of such determination, the “Determination Date”). To the extent earned, the PSUs will vest as set forth in Section 2.1(c).
(b) Change in Control. Notwithstanding Section 2.1(a), if a Change in Control occurs on or prior to the last day of the Performance Period, the PSUs will be earned on the date of the Change in Control or an earlier date determined by the Administrator (the date of such determination, the “CIC Determination Date”) and the number of earned PSUs will equal the greater of (i) 100% of the Target
Number of PSUs and (ii) the sum of the number of earned EBITDA PSUs and earned Revenue PSUs using the Company’s expected full year performance based on its then current year-to-date results, in each case, as determined by the Administrator prior to the date of the Change in Control; provided that, if the Administrator does not make such a determination or determines that there is insufficient information to accurately estimate the Company’s full year performance, the number of earned PSUs will equal the Target Number of PSUs. Any PSUs that have not been earned will be automatically forfeited on the CIC Determination Date unless the Administrator otherwise determines.
(c) Vesting of Earned PSUs; Forfeiture. The earned PSUs will vest as to one-third on each of the Determination Date or the CIC Determination Date, as applicable, and the first and second anniversaries thereof. Any fraction of a PSU that would otherwise be vested will be accumulated and will vest only when a whole PSU has accumulated. In the event of Participant’s Termination of Service for any reason, all unvested PSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Dividend Equivalents (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the corresponding PSU.
2.2 Settlement.
(a) PSUs and Dividend Equivalents (including any Dividend Equivalent Account balance) will be paid in Shares or cash at the Administrator’s option as soon as administratively practicable after the vesting of the applicable PSU, but in no event more than sixty (60) days after the PSU’s vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.
(b) If a PSU is paid in cash, the amount of cash paid with respect to the PSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date. If a Dividend Equivalent is paid in Shares, the number of Shares paid with respect to the Dividend Equivalent will equal the quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date.
ARTICLE III.
TAXATION AND TAX WITHHOLDING
3.1 Representation. Participant represents to the Company that Participant has reviewed with Participant’s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.
3.2 Tax Withholding.
(a) The Company has the right and option, but not the obligation, to treat Participant’s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the PSUs or Dividend Equivalents as Participant’s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.
(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs and the Dividend Equivalents, regardless of any action the
A-2
Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs or Dividend Equivalents. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the Dividend Equivalents or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the PSUs or Dividend Equivalents to reduce or eliminate Participant’s tax liability.
ARTICLE IV.
OTHER PROVISIONS
4.1 Adjustments. Participant acknowledges that the PSUs, the Shares subject to the PSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.
4.2 Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company’s Secretary at the Company’s principal office or the Secretary’s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant’s last known mailing address, email address or facsimile number in the Company’s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.
4.3 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
4.4 Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.
4.5 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.
4.6 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the PSUs and the Dividend Equivalents will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.
4.7 Entire Agreement. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.
A-3
4.8 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.
4.9 Limitation on Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs and Dividend Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement.
4.10 Not a Contract of Employment. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.
4.11 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.
* * * * *
A-4
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/20 | ||||
| Filed on: | 4/29/20 | 8-K | ||
| For Period end: | 3/31/20 | |||
| 3/2/20 | 4 | |||
| 1/1/20 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Teladoc Health, Inc. 10-K 12/31/20 126:15M Toppan Merrill Bridge/FA 11/06/20 Teladoc Health, Inc. S-8 11/06/20 5:185K Toppan Merrill/FA 11/06/20 Teladoc Health, Inc. S-8 POS 11/06/20 4:90K Toppan Merrill/FA 11/05/20 Teladoc Health, Inc. S-3ASR 11/05/20 4:322K Toppan Merrill-FA 9/15/20 Livongo Health, Inc. DEFM14A 9/15/20 1:7.1M Broadridge Fin’l So… Inc 9/15/20 Teladoc Health, Inc. 424B3 1:5.3M Broadridge Fin’l So… Inc 9/11/20 Teladoc Health, Inc. S-4/A 8:10M Broadridge Fin’l So… Inc 9/03/20 Teladoc Health, Inc. S-4 8:6.1M Broadridge Fin’l So… Inc |